Medivir sharpens rare-disease and liver cancer focus after financing and licensing deals

Medivir AB ( (SE:MVIR) ) has shared an announcement.

Medivir reported improved financial performance in 2025, with higher net turnover, reduced EBITDA losses and year-end cash nearly doubling to SEK 119.2 million, supported by a SEK 151 million rights issue and a subsequent SEK 45 million directed share issue to Carl Bennet AB. This bolstered balance sheet gives the company the means to advance a randomized second-line liver cancer trial of fostrox plus Lenvima and to restart clinical development of MIV-711 in Osteogenesis Imperfecta, a rare bone disorder with no approved therapies.

Strategically, Medivir deepened its partnering model by out-licensing topical HDAC inhibitor remetinostat to Canadian firm Biossil under a deal worth up to about USD 60 million plus royalties, and by benefiting from strong proof-of-concept data and a new confirmatory study for veterinary candidate VBX-1000 (MIV-701) through partner Vetbiolix. The FDA’s Orphan Drug Designation for MIV-711 in Osteogenesis Imperfecta and the capital-efficient Vetbiolix deal together strengthen Medivir’s long-term revenue prospects, with management highlighting potential royalty flows from MIV-701 alone that could approximate the company’s current market value several years after launch, enhancing its position in oncology and rare-disease drug development.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish biopharmaceutical company listed on Nasdaq Stockholm Small Cap that develops innovative therapies for diseases with high unmet medical need. Its lead programs include fostrox, a precision chemotherapy targeting liver cancer cells while limiting side effects, and MIV-711, a selective cathepsin K inhibitor for Osteogenesis Imperfecta, both viewed as potential blockbuster assets in niche oncology and rare disease markets. Collaborations and licensing agreements are central to Medivir’s business model, with several candidates developed and commercialized through partners to create scalable, capital-efficient revenue streams.

Average Trading Volume: 4,080,936

Technical Sentiment Signal: Sell

Current Market Cap: SEK528.5M

See more data about MVIR stock on TipRanks’ Stock Analysis page.